On November 9, 2017 Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving people with rare diseases, reported the broad range of research it will present at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, taking place December 9-12, 2017, in Atlanta, Georgia (Press release, Shire, NOV 9, 2017, View Source [SID1234521927]). Shire’s presence at ASH (Free ASH Whitepaper) spans its hematology and oncology franchises with 2 oral presentations and 7 poster presentations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Shire’s commitment to fighting rare disease, particularly in hematology and oncology, is reflected in the company’s strong presence at ASH (Free ASH Whitepaper), one of the world’s premier medical conferences focused on blood disorders," said Howard B. Mayer, M.D., SVP and ad-interim Head, Global Research and Development, Shire. "We are committed to continuous and ambitious innovation that helps advance the standards of care and improves outcomes in these therapeutic categories where there remains significant unmet patient need."
HEMATOLOGY
The research presented at ASH (Free ASH Whitepaper) will showcase Shire’s broad hematology portfolio, which covers a wide range of rare bleeding indications and highlights real-world safety and efficacy data. In addition to presenting new research, Shire will share updates related to its ongoing innovation and promising pipeline of investigational treatments. Shire has provided a grant to support a satellite symposium at ASH (Free ASH Whitepaper) hosted by CMEology that is focused on the latest strategies and innovations to help advance best practices in the management of hemophilia:
Advancing Standards in the Management of Hemophilia A: Contemporary Strategies and Innovations. Friday, December 8, 2017, 6:00-10:00 p.m. EST. Hyatt Regency Atlanta, International Ballroom North. For more details or to register, visit: View Source
ONCOLOGY
Shire’s expertise in rare and difficult-to-treat cancers includes ongoing research into investigational pegylated asparaginase, as a component of antineoplastic combination therapy in acute lymphoblastic leukemia (ALL). The company’s pipeline in oncology includes assets being developed for the treatment of metastatic pancreatic cancer, ALL, lung cancer, as well as early stage checkpoint inhibitor and allogeneic CAR T targets. At ASH (Free ASH Whitepaper) 2017, Shire is co-supporting an Independent Medical Education program organized by prIME-Oncology on:
Optimizing Management of Acute Lymphoblastic Leukemia: From Adolescence to Adults. Friday, December 8, 2017, 12:30-4:30 p.m. EST. Hyatt Regency Atlanta, International Ballroom North. For more details or to register, visit: View Source
For further information please contact:
Investor Relations
Ian Karp [email protected] +1 781 482 9018
Robert Coates [email protected] +44 203 549 0874
Media
Gwen Fisher [email protected] +1 781 482 9649
Molly Poarch [email protected] +1 312 965 3413